Item 8.01 Other Events.

On January 21, 2020, Genprex, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had granted Fast Track Designation for the Company's Oncoprex™ immunogene therapy in combination with epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca's Tagrisso®) for the treatment of non-small cell lung cancer patients with EFGR mutations that progressed after treatment with osimertinib alone. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
Number     Description
 99.1        Press Release dated January 21, 2020, issued by Genprex, Inc.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses